Charlotte Albaek Thrue

USPTO Granted Patents = 19 (Patent Applications = 9)

CIPO Patents = 2 (Patent Applications = 2)

EPO Patents = 5 (Patent Applications = 1)

Average Co-Inventor Count = 4.8

ph-index = 8

Forward Citations = 627(Granted Patents)

Location History:

Residence Not Provided, DK (2009)
Copenhagen, DK (2010 - 2013)
Kobenhavn, DK (2014)
København K, DK (2009 - 2015)
Kobenhaven K, DK (2016)
Hoersholm, DK (2016)
Kobenhavn K, DK (2010 - 2018)
Hampshire, GB (2017 - 2018)

Company Filing History:

Enzon Pharmaceuticals, Inc.

patents

7 out of 46

Roche Innovation Center Copenhagen A/s

where one patent can have more than one assignee

Years Active: 2009-2018

Loading Chart...

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9994850 - Antisense design (2018-06-12),

2. 9951333 - Antisense design (2018-04-24),

3. 9938527 - Potent LNA oligonucleotides for the inhibition of HIF-1A expression (2018-04-10),

4. 9890383 - Antisense design (2018-02-13),

5. 9708614 - Antisense design (2017-07-18),

6. 9447138 - Potent LNA oligonucleotides for the inhibition of HIF-1a expression (2016-09-20),

7. 9428534 - Antisense design (2016-08-30),

8. 9045518 - Amino-LNA, thio-LNA and alpha-L-oxy-LN (2015-06-02),

9. 8785617 - Oligomeric compounds for the modulation of HIF-1A expression (2014-07-22),

10. 8410071 - Potent LNA oligonucleotides for the inhibition of HIF-1A expression (2013-04-02),

11. 8357670 - Oligomeric compounds for the modulation of HIF-1A expression (2013-01-22),

12. 8207140 - Oligomeric compounds for the modulation of HIF-1α expression (2012-06-26),

13. 8026355 - Oligomeric compounds for the modulation of survivin expression (2011-09-27),

14. 7939507 - Potent LNA oligonucleotides for the inhibition of HIF-1a expression (2011-05-10),

15. 7846911 - Oligomeric compounds for the modulation of HIF-1alpha expression (2010-12-07),

Title: Innovator Spotlight: Charlotte Albaek Thrue

Introduction: Charlotte Albaek Thrue is a prominent inventor based in Kobenhavn K, Denmark. With a remarkable portfolio of 19 patents, she has made significant contributions to the pharmaceutical industry, particularly in the field of antisense therapies. Her innovative work has garnered attention and admiration from peers and organizations alike.

Latest Patents: Among her latest inventions is a novel class of pharmaceuticals that incorporates Locked Nucleic Acid (LNA), utilized in antisense therapy. These innovative oligonucleotides exhibit enhanced antisense properties and consist of at least one LNA selected from beta-D-thio/amino-LNA or alpha-L-oxy/thio/amino-LNA. The oligonucleotides may also integrate DNA and/or RNA nucleotides, signaling a significant advancement in targeted therapies.

Career Highlights: Charlotte has had an impactful career in the biotechnology and pharmaceutical sectors. She has worked at leading companies such as Santaris Pharma A/S and Enzon Pharmaceuticals, Inc., where she has been instrumental in developing cutting-edge therapies. Her dedication and expertise showcase her commitment to advancing healthcare through innovation.

Collaborations: Throughout her career, Charlotte has collaborated with talented colleagues, including Majken Westergaard and Henrik Frydenlund Hansen. These partnerships have been key in driving her research and furthering the impact of her inventions in the medical field.

Conclusion: Charlotte Albaek Thrue exemplifies the spirit of innovation in the realm of pharmaceuticals. With her impressive array of patents and successful collaborations, she continues to pave the way for future advancements in antisense therapy and beyond. Her work not only illustrates the importance of creativity in science but also highlights the potential for transformative health solutions.

This text is generated by artificial intelligence and may not be accurate.